

## Peter Mac publications 2023

### January

1. Alamgeer M, Coleman A, McDowell L, Giddings C, Safdar A, Sigston E, Wang Y, Subramaniam A. Treatment outcomes of standard (high dose) cisplatin and non-standard chemotherapy for locally advanced head and neck cancer. *Cancer Rep* 2023;6:e1674.
2. Ali LR, Garrido-Castro AC, Lenehan PJ, Bollenrucher N, Stump CT, Dougan M, Goel S, Shapiro GI, Tolaney SM, Dougan SK. PD-1 blockade and CDK4/6 inhibition augment nonoverlapping features of T cell activation in cancer. *J Exp Med* 2023;220:e20220729.
3. Angenendt L, Rollig C, Montesinos P, Ravandi F, Juliusson G, Recher C, Itzykson R, Racil Z, Wei AH, Schliemann C. Revisiting coexisting chromosomal abnormalities in NPM1-mutated AML in light of the revised ELN 2022 classification. *Blood* 2023;141:433-5.
4. Aranda S, Jefford M. Social inequity and cancer. *Asia Pac J Oncol Nurs* 2023;10:100178.
5. Ascierto PA, Stroyakovskiy D, Gogas H, Robert C, Lewis K, Protsenko S, Pereira RP, Eigentler T, Rutkowski P, Demidov L, Zhukova N, Schachter J, Yan Y, Caro I, Hertig C, Xue C, Kusters L, McArthur GA, Gutzmer R. Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAF<sup>V600</sup> mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study. *Lancet Oncol* 2023;24:33-44.
6. Ayati N, Herrmann K, Fanti S, Murphy DG, Hofman MS. More Accurate Imaging Is Not Stage Migration: Time to Move from "Hubble" to "Webb" in Hormone-sensitive Prostate Cancer. *Eur Urol* 2023;83:6-9.
7. Balasubramanian A, John T. Safety of Dueling NSCLC With Dual Agent Immunotherapy. *J Thorac Oncol* 2023;18:10-13.
8. Ballinger ML, Pattnaik S, Mundra PA, Zaheed M, Rath E, Priestley P, Baber J, Ray-Coquard I, Isambert N, Causeret S, van der Graaf WTA, Puri A, Duffaud F, Le Cesne A, Seddon B, Chandrasekar C, Schiffman JD, Brohl AS, James PA, Kurtz JE, Penel N, Myklebost O, Meza-Zepeda LA, Pickett H, Kansara M, Waddell N, Kondrashova O, Pearson JV, Barbour AP, Li S, Nguyen TL, Fatkin D, Graham RM, Giannoulatou E, Green MJ, Kaplan W, Ravishankar S, Coptly J, Powell JE, Cuppen E, van Eijk K, Veldink J, Ahn JH, Kim JE, Randall RL, Tucker K, Judson I, Sarin R, Ludwig T, Genin E, Deleuze JF, Haber M, Marshall G, Cairns MJ, Blay JY, Thomas DM, Tattersall M, Neuhaus S, Lewis C, Tucker K, Carey-Smith R, Wood D, Porceddu S, Dickinson I, Thorne H, James P, Ray-Coquard I, Blay JY, Cassier P, Le Cesne A, Duffaud F, Penel N, Isambert N, Kurtz JE, Puri A, Sarin R, Ahn JH, Kim JE, Ward I, Judson I, van der Graaf W, Seddon B, Chandrasekar C, Rickar R, Hennig I, Schiffman J, Randall RL, Silvestri A, Zaratzian A, Tayao M, Walwyn K, Niedermayr E, Mang D, Clark R, Thorpe T, MacDonald J, Riddell K, Mar J, Fennelly V, Wicht A, Zielony B, Galligan E, Glavich G, Stoeckert J, Williams L, Djandjgava L, Buettner I, Osinki C, Stephens S, Rogasik M, Bouclier L, Girodet M, Charreton A, Fayet Y, Crasto S, Sandupatla B, Yoon Y, Je N, Thompson L, Fowler T, Johnson B, Petrikova G, Hambridge T, Hutchins A, Bottero D, Scanlon D, Stokes-Denson J, Génin E, Champion D, Dartigues JF, Deleuze JF, Lambert JC, Redon R, Ludwig T, Grenier-Boley B, Letort S, Lindenbaum P, Meyer V, Quenez O, Dina C, Bellenguez C, Le Clézio CC, Giemza J, Chatel S, Férec C, Le Marec H, Letenneur L, Nicolas G, Rouault K. Heritable defects in telomere and mitotic function selectively predispose to sarcomas. *Science* 2023;379:253-60.
9. Bennett N, Malloy MJ, Atkins SE, Gonelli S, Worth LJ. The same but different: a comparison of *Staphylococcus aureus* bloodstream infections in metropolitan and non-metropolitan hospitals (2010-2020). *Intern Med J* 2023;53:89-94.
10. Biben C, Weber TS, Potts KS, Choi J, Miles DC, Carmagnac A, Sargeant T, de Graaf CA, Fennell KA, Farley A, Stonehouse OJ, Dawson MA, Hilton DJ, Naik SH, Taoudi S. In vivo clonal tracking reveals evidence of haemangioblast and haematomesoblast contribution to yolk sac haematopoiesis. *Nat Commun* 2023;14:41.
11. Bradford A, Young K, Whitechurch A, Burbury K, Pearson EJM. Disabled, invisible and dismissed-The lived experience of fatigue in people with myeloproliferative neoplasms. *Cancer Rep* 2023;6:e1655.

12. Brown D, Loeliger J, Stewart J, Graham KL, Goradia S, Gerges C, Lyons S, Connor M, Stewart S, Di Giovanni A, D'Angelo S, Kiss N. Relationship between global leadership initiative on malnutrition (GLIM) defined malnutrition and survival, length of stay and post-operative complications in people with cancer: A systematic review. *Clin Nutr* 2023;42:255-68.
13. Brusco NK, Bury S, Chua KYL, Vogrin S, Holmes NE, Trubiano JA. Penicillin Allergy Delabeling Program: an exploratory economic evaluation in the Australian context. *Intern Med J* 2023;53:74-83.
14. Casulo C, Herold M, Hiddemann W, Iyengar S, Marcus RE, Seymour JF, Launonen A, Knapp A, Nielsen TG, Mir F. Risk Factors for and Outcomes of Follicular Lymphoma Histological Transformation at First Progression in the GALLIUM Study. *Clin Lymphoma Myeloma Leuk* 2023;23:40-8.
15. Chann AS, Charnley M, Newton LM, Newbold A, Wiede F, Tiganis T, Humbert PO, Johnstone RW, Russell SM. Stepwise progression of  $\beta$ -selection during T cell development involves histone deacetylation. *Life Sci Alliance* 2023;6:e202201645.
16. Chann AS, Chen Y, Kinwel T, Humbert PO, Russell SM. Scribble and E-cadherin cooperate to control symmetric daughter cell positioning by multiple mechanisms. *J Cell Sci* 2023;136:jcs260547.
17. Charnley M, Allam AH, Newton LM, Humbert PO, Russell SM. E-cadherin in developing murine T cells controls spindle alignment and progression through  $\beta$ -selection. *Sci Adv* 2023;9:eade5348.
18. Chen K, Lawrentschuk N. Case of the Month from Peter MacCallum Cancer Centre, Melbourne, Australia: ICG-assisted robotic Boari flap ureteric reimplantation in a case of missed ureteric injury. *BJU Int* 2023;131:46-9.
19. Chi KN, Barnicle A, Sibilla C, Lai Z, Corcoran C, Barrett JC, Adelman CA, Qiu P, Easter A, Dearden S, Oxnard GR, Agarwal N, Azad A, de Bono J, Mateo J, Olmos D, Thiery-Vuillemin A, Harrington EA. Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound. *Clin Cancer Res* 2023;29:81-91.
20. Chong CY, Goh MS, Porceddu SV, Rischin D, Lim AM. The Current Treatment Landscape of Cutaneous Squamous Cell Carcinoma. *Am J Clin Dermatol* 2023;24:25-40.
21. Chou HH, Fereday S, DeFazio A, Chang CL, Bowtell D, Hsu HC, Traficante N, Jeong SY, Cheng WF, Ariyaratne D, Tung T, Rajadhyaksha V, Lee WH, Brown D, Kim BG. Contrasting clinical characteristics and treatment patterns in women with newly diagnosed advanced-stage epithelial ovarian cancer in Australia, South Korea and Taiwan. *J Gynecol Oncol* 2023;34:e3.
22. Chua BH, Link EK, Kunkler IH, Olivotto IA. Breast radiotherapy for non-low-risk ductal carcinoma in situ: to boost or not to boost? - Authors' reply. *Lancet* 2023;401:24.
23. D'Costa I, Hunt I, Russell L, Adams K. A racial bias test with tertiary cancer centre employees: why anti-racist measures are required for First Nations Australians cancer care equity. *Aust Health Rev* 2023;47:5-12.
24. Daniell JR, Rowe D, Wiesenfeld D, McDowell L, Hall KA, Nastri A, Iseli TA, Wong T. A change in surgical margin: do wider surgical margins lead to decreased rates of local recurrence in T1 and T2 oral tongue cancer? *Int J Oral Maxillofac Surg* 2023;52:19-25.
25. de la Fuente MI, Colman H, Rosenthal M, Van Tine BA, Levacic D, Walbert T, Gan HK, Vieito M, Milhem MM, Lipford K, Forsyth S, Guichard SM, Mikhailov Y, Sedkov A, Brevard J, Kelly PF, Mohamed H, Monga V. Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial. *Neuro Oncol* 2023;25:146-56.
26. Drilon A, Subbiah V, Gautschi O, Tomasini P, de Braud F, Solomon BJ, Shao-Weng Tan D, Alonso G, Wolf J, Park K, Goto K, Soldatenkova V, Szymczak S, Barker SS, Puri T, Bence Lin A, Loong H, Besse B. Selpercatinib in Patients with RET Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy from the Registrational LIBRETTO-001 Phase I/II Trial. *J Clin Oncol* 2023;41:385-94.
27. Flore J, Kokanović R, Broom A, Heynemann S, Lai-Kwon J, Jefford M. Entanglements and imagined futures: The subject(s) of precision in oncology. *Soc Sci Med* 2023;317:115608.

28. Fossouo Tagne J, Yakob RA, Dang TH, McDonald R, Wickramasinghe N. Reporting, Monitoring, and Handling of Adverse Drug Reactions in Australia: Scoping Review. *JMIR Public Health Surveill* 2023;9:e40080.
29. Fowler NH, Dickinson M, Ghosh M, Chen AI, Andreadis C, Tiwari R, Masood A, Ramos R, Jousseume E, Thieblemont C, Dreyling M, Schuster SJ. Assessment of Healthcare Resource Utilization and Hospitalization Costs in Patients With Relapsed or Refractory Follicular Lymphoma Undergoing CAR-T Cell Therapy With Tisagenlecleucel: Results From the ELARA Study. *Transplant Cell Ther* 2023;29:60.e1-60.e4.
30. Fox LC, Blombery P. Matching phenotypes through mismatching genomics. *Leuk Lymphoma* 2023;64:1-2.
31. Fremond S, Andani S, Barkey Wolf J, Dijkstra J, Melsbach S, Jobsen JJ, Brinkhuis M, Roothaan S, Jurgenliemk-Schulz I, Lutgens L, Nout RA, van der Steen-Banasik EM, de Boer SM, Powell ME, Singh N, Mileskin LR, Mackay HJ, Leary A, Nijman HW, Smit V, Creutzberg CL, Horeweg N, Koelzer VH, Bosse T. Interpretable deep learning model to predict the molecular classification of endometrial cancer from haematoxylin and eosin-stained whole-slide images: a combined analysis of the PORTEC randomised trials and clinical cohorts. *Lancet Digit Health* 2023;5:e71-e82.
32. Frenzl D. Editorial Comment. *J Urol* 2023;209:168-9.
33. Gaudreault M, Korte J, Bucknell N, Jackson P, Sakyanun P, McIntosh L, Woon B, Buteau JP, Hofman MS, Mulcahy T, Kron T, Siva S, Hardcastle N. Comparison of dual-energy CT with positron emission tomography for lung perfusion imaging in patients with non-small cell lung cancer. *Phys Med Biol* 2023;68:035015.
34. Girard N, Bar J, Garrido P, Garassino MC, McDonald F, Mornex F, Filippi AR, Smit HJM, Peters S, Field JK, Christoph DC, Sibille A, Fietkau R, Haakensen VD, Chouaid C, Markman B, Hiltermann TJN, Taus A, Sawyer W, Allen A, Chander P, Licour M, Solomon B. Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study. *J Thorac Oncol* 2023;18:181-93.
35. Hardcastle N, Gaudreault M, Yeo AU, Ungureanu E, Markham C, Barnes R, Chander S, Chu J. Selection of motion management in liver stereotactic body radiotherapy and its impact on treatment time. *Phys Imaging Radiat Oncol* 2023;25:100407.
36. Harrington KJ, Burtress B, Greil R, Soulieres D, Tahara M, de Castro G Jr, Psyrri A, Brana I, Baste N, Neupane P, Bratland A, Fuehrer T, Hughes BGM, Mesia R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Lin J, Gumuscu B, Swaby RF, Rischin D. Pembrolizumab with or without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study. *J Clin Oncol* 2023;41:790-802.
37. Hasegawa K, Wei AH, Garcia-Manero G, Daver NG, Rajakumaraswamy N, Iqbal S, Chan RJ, Hu H, Tse P, Yan J, Zoratti MJ, Xie F, Sallman DA. Azacitidine Monotherapy in Patients With Treatment-Naive Higher-risk Myelodysplastic Syndrome: A Systematic Literature Review and Meta-analysis. *Clin Lymphoma Myeloma Leuk* 2023;23:127-37.
38. Healey JH, Tap WD, Gelhorn HL, Ye X, Speck RM, Palmerini E, Stacchiotti S, Desai J, Wagner AJ, Alcindor T, Ganjoo K, Martin-Broto J, Wang Q, Shuster D, Gelderblom H, van de Sande M. Pexidartinib Provides Modest Pain Relief in Patients With Tenosynovial Giant Cell Tumor: Results From ENLIVEN. *Clin Orthop Relat Res* 2023;481:107-16.
39. Hiltemann S, Rasche H, Gladman S, Hotz HR, Larivière D, Blankenberg D, Jagtap PD, Wollmann T, Bretauudeau A, Goué N, Griffin TJ, Royaux C, Le Bras Y, Mehta S, Syme A, Coppens F, Droesbeke B, Soranzo N, Bacon W, Psomopoulos F, Gallardo-Alba C, Davis J, Föll MC, Fahrner M, Doyle MA, Serrano-Solano B, Fouilloux AC, van Heusden P, Maier W, Clements D, Heyl F, Grüning B, Batut B. Galaxy Training: A powerful framework for teaching! *PLoS Comput Biol* 2023;19:e1010752.

40. Hurvitz SA, Hegg R, Chung WP, Im SA, Jacot W, Ganju V, Chiu JWY, Xu B, Hamilton E, Madhusudan S, Iwata H, Altintas S, Henning JW, Curigliano G, Perez-Garcia JM, Kim SB, Petry V, Huang CS, Li W, Frenel JS, Antolin S, Yeo W, Bianchini G, Loi S, Tsurutani J, Egorov A, Liu Y, Cathcart J, Ashfaq S, Cortés J. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. *Lancet* 2023;401:105-17.
41. Hussain T, Nguyen A, Daunt C, Thiele D, Pang ES, Li J, Zaini A, O'Keeffe M, Zaph C, Harris NL, Quinn KM, La Gruta NL. Helminth Infection-Induced Increase in Virtual Memory CD8 T Cells Is Transient, Driven by IL-15, and Absent in Aged Mice. *J Immunol* 2023;210:297-309.
42. Jenkins LJ, Luk IY, Fairlie WD, Lee EF, Palmieri M, Schoffer KL, Tan T, Ng I, Vukelic N, Tran S, Tse JWT, Nightingale R, Alam Z, Chionh F, Iatropoulos G, Ernst M, Afshar-Sterle S, Desai J, Gibbs P, Sieber OM, Dhillon AS, Tebbutt NC, Mariadason JM. Genotype-Tailored ERK/MAPK Pathway and HDAC Inhibition Rewires the Apoptotic Rheostat to Trigger Colorectal Cancer Cell Death. *Mol Cancer Ther* 2023;22:52-62.
43. John A, Spain L, Hamid AA. Navigating the Current Landscape of Non-Clear Cell Renal Cell Carcinoma: A Review of the Literature. *Curr Oncol* 2023;30:923-37.
44. Kelly BD, O'Brien JS, Lundon DJ. Editorial Comment. *J Urol* 2023;209:168.
45. Kelly R, Jensen A, Karunaratna N, Wong S, Shapiro J, Weickhardt A, Parente P, Azad AA, Uccellini A, Torres J, Parnis F, Goh J, Kwan EM, Brown S, Steer C, Warren M, Gibbs P, Tran B, Anton A. Prostate-specific membrane antigen positron emission tomography-computed tomography use prior to systemic therapy in metastatic castration-resistant prostate cancer. *BJU Int* 2023;131:179-82.
46. Kern W, Westers TM, Bellos F, Bene MC, Bettelheim P, Brodersen LE, Burbury K, Chu SC, Cullen M, Porta MD, Dunlop AS, Johansson U, Matarraz S, Oelschlaegel U, Ogata K, Porwit A, Preijers F, Psarra K, Saft L, Subirá D, Weiß E, van der Velden VHJ, van de Loosdrecht A. Multicenter prospective evaluation of diagnostic potential of flow cytometric aberrancies in myelodysplastic syndromes by the ELN iMDS flow working group. *Cytometry B Clin Cytom* 2023;104:51-65.
47. Kriachkov V, Ormsby AR, Kusnadi EP, McWilliam HEG, Mintern JD, Amarasinghe SL, Ritchie ME, Furic L, Hatters DM. Arginine-rich C9ORF72 ALS proteins stall ribosomes in a manner distinct from a canonical ribosome-associated quality control substrate. *J Biol Chem* 2023;299:102774.
48. Krigstein M, Iland HJ, Wei AH. Applying molecular measurable residual disease testing in acute myeloid leukaemia. *Pathology* 2023;55:1-7.
49. Kuswanto CN, Sharp J, Stafford L, Schofield P. Fear of cancer recurrence as a pathway from fatigue to psychological distress in mothers who are breast cancer survivors. *Stress Health* 2023;39:197-208.
50. Lew TE, Minson A, Dickinson M, Handunnetti SM, Blombery P, Khot A, Anderson MA, Ritchie D, Tam CS, Seymour JF. Treatment approaches for patients with TP53-mutated mantle cell lymphoma. *Lancet Haematol* 2023;10:e142-54.
51. Li N, Zethoven M, McInerney S, Healey E, DeSilva D, Devereux L, Scott RJ, James PA, Campbell IG. Contribution of large genomic rearrangements in PALB2 to familial breast cancer: implications for genetic testing. *J Med Genet* 2023;60:112-8.
52. Lobachevsky P, Skene C, Munforte L, Smith A, White J, Martin RF. An approach to assessing the contribution of the high LET effect in strategies for Auger endoradiotherapy. *Int J Radiat Biol* 2023;99:95-102.
53. Lobb RJ, Visan KS, Wu LY, Norris EL, Hastie ML, Everitt S, Yang IA, Bowman RV, Siva S, Larsen JE, Gorman JJ, MacManus M, Leimgruber A, Fong KM, Möller A. An epithelial-to-mesenchymal transition induced extracellular vesicle prognostic signature in non-small cell lung cancer. *Commun Biol* 2023;6:68.

54. Loeliger J, Dewar S, Kiss N, Dumbrell J, Elliott A, Kaegi K, Kelaart A, McIntosh R, Swan W, Stewart J. Co-design of a cancer nutrition care pathway by patients, carers, and health professionals: the CanEAT pathway. *Support Care Cancer* 2023;31:99.
55. Loft M, Lok SW, De Boer R, Malik L, Greenberg S, Yeo B, Anton A, Nottage M, Wong V, Nott L, Collins IM, Torres J, Barnett F, Lombard JM, Gibbs P, Gately L. Addition of endocrine therapy to dual anti-HER2 targeted therapy in initial treatment of HER2 + /HR + metastatic breast cancer. *Breast Cancer Res Treat* 2023;198:67-74.
56. Lok SW, De Boer R, Baron-Hay S, Button P, Devitt B, Forster BC, Fox P, Harold M, Ketheeswaran S, Kichenadasse G, Kiely BE, Marx G, Nott L, Pellegrini L, Tafreshi A, Gibbs P. Pertuzumab study in the neoadjuvant setting for HER2-positive nonmetastatic breast cancer in Australia (PeRSIA). *Int J Cancer* 2023;152:267-75.
57. Lupat R, Perera R, Loi S, Li J. Moanna. Multi-Omics Autoencoder-Based Neural Network Algorithm for Predicting Breast Cancer Subtypes. *IEEE Access* 2023;11:10912-10924.
58. Lynch F, Meng Y, Best S, Goranitis I, Savulescu J, Gyngell C, Vears DF. Australian public perspectives on genomic data storage and sharing: Benefits, concerns and access preferences. *Eur J Med Genet* 2023;66:104676.
59. MacFarling Meure C, Steer B, Porter J. Interrelationships between Dietary Outcomes, Readmission Rates and Length of Stay in Hospitalised Oncology Patients: A Scoping Review. *Nutrients* 2023;15:400.
60. Makishima H, Saiki R, Nannya Y, Korotev S, Gurnari C, Takeda J, Momozawa Y, Best S, Krishnamurthy P, Yoshizato T, Atsuta Y, Shiozawa Y, Iijima-Yamashita Y, Yoshida K, Shiraishi Y, Nagata Y, Kakiuchi N, Onizuka M, Chiba K, Tanaka H, Kon A, Ochi Y, Nakagawa MM, Okuda R, Mori T, Yoda A, Itonaga H, Miyazaki Y, Sanada M, Ishikawa T, Chiba S, Tsurumi H, Kasahara S, Müller-Tidow C, Takaori-Kondo A, Ohyashiki K, Kiguchi T, Matsuda F, Jansen JH, Polprasert C, Blombery P, Kamatani Y, Miyano S, Malcovati L, Haferlach T, Kubo M, Cazzola M, Kulasekararaj AG, Godley LA, Maciejewski JP, Ogawa S. Germ line DDX41 mutations define a unique subtype of myeloid neoplasms. *Blood* 2023;141:534-49.
61. Marston C, Morgan DD, Philip J, Agar M. Supporting Carers as Patients Move between Hospital and Home: A Systematic Review of Interventions to Support These Transitions in Care. *J Palliat Med* 2023;26:270-98.
62. Mavropalias G, Cormie P, Peddle-McIntyre CJ, Galvao DA, Taaffe DR, Schofield C, Ray S, Zissiadis Y, Newton RU. The effects of home-based exercise therapy for breast cancer-related fatigue induced by radical radiotherapy. *Breast Cancer* 2023;30:139-50.
63. McDowell L, Rischin D, King M, Kenny L, Porceddu S, Wratten C, Macann A, Jackson JE, Bressel M, Fua T, Lin C, Liu C, Corry J. Patient- and Clinician-Reported Outcomes in Human Papillomavirus-Associated Tonsillar Carcinoma Treated with Unilateral and Bilateral Intensity Modulated Radiation Therapy-A Substudy From TROG 12.01. *Int J Radiat Oncol Biol Phys* 2023;115:174-88.
64. Meagher NS, Hamilton P, Milne K, Thornton S, Harris B, Weir A, Alsop J, Bisinoto C, Brenton JD, Brooks-Wilson A, Chiu DS, Cushing-Haugen KL, Fereday S, Garsed DW, Gayther SA, Gentry-Maharaj A, Gilks B, Jimenez-Linan M, Kennedy CJ, Le ND, Piskorz AM, Riggan MJ, Shah M, Singh N, Talhouk A, Widschwendter M, Bowtell DDL, Candido Dos Reis FJ, Cook LS, Fortner RT, García MJ, Harris HR, Huntsman DG, Karnezis AN, Köbel M, Menon U, Pharoah PDP, Doherty JA, Anglesio MS, Pike MC, Pearce CL, Friedlander ML, DeFazio A, Nelson BH, Ramus SJ. Profiling the immune landscape in mucinous ovarian carcinoma. *Gynecol Oncol* 2023;168:23-31.
65. Meric-Bernstam F, Sweis RF, Kasper S, Hamid O, Bhatia S, Dummer R, Stradella A, Long GV, Spreafico A, Shimizu T, Steeghs N, Luke JJ, McWhirter SM, Muller T, Nair N, Lewis N, Chen X, Bean A, Kattenhorn L, Pelletier M, Sandhu S. Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study. *Clin Cancer Res* 2023;29:110-21.

66. Miller AR. Checkpoint inhibitors are a basic science-based, transformative new treatment for lung cancer. *Respirology* 2023;28:101-6.
67. Milley K, Chima S, Karnchanachari N, McNamara M, Druce P, Emery J. General practice-based cancer research publications: a bibliometric analysis 2013-2019. *Br J Gen Pract* 2023;73:e133-40.
68. Mitchell C, Malalasekera V, Gill AJ, Vissers JHA, Luen SJ, Grimmond SM, Lewin J. Primary pancreatic spindle cell sarcoma with a TMEM106B::BRAF gene fusion treated with MEK inhibition. *Pathology* 2023;55:127-9.
69. Molania R, Foroutan M, Gagnon-Bartsch JA, Gandolfo LC, Jain A, Sinha A, Olshansky G, Dobrovic A, Papenfuss AT, Speed TP. Removing unwanted variation from large-scale RNA sequencing data with PRPS. *Nat Biotechnol* 2023;41:82-95.
70. Mordant FL, Price OH, Rudraraju R, Slavin MA, Marshall C, Worth LJ, Peck H, Barr IG, Sullivan SG, Subbarao K. Antibody titres elicited by the 2018 seasonal inactivated influenza vaccine decline by 3 months post-vaccination but persist for at least 6 months. *Influenza Other Respir Viruses* 2023;17:e13072.
71. Morgan KJ, Doggett K, Geng F, Mieruszynski S, Whitehead L, Smith KA, Hogan BM, Simons C, Baillie GJ, Molania R, Papenfuss AT, Hall TE, Ober EA, Stainier DYR, Gong Z, Heath JK. *ahctf1* and *kras* mutations combine to amplify oncogenic stress and restrict liver overgrowth in a zebrafish model of hepatocellular carcinoma. *Elife* 2023;12:e73407.
72. Nedumannil R, Ritchie D, Bajel A, Ng AP, Harrison SJ, Westerman D. Real-world utility of early measurable residual disease assessments by multi-parametric flow cytometry in adult patients with B-lymphoblastic leukemia receiving Hyper-CVAD induction chemotherapy. *Eur J Haematol* 2023;110:168-76.
73. Nguyen PC, Tiong IS, Westerman DA, Blombery P. A novel ATRX variant with splicing consequences in myelodysplastic syndrome with acquired alpha thalassaemia. *Br J Haematol* 2023;200:e13-e16.
74. Nugawela D, Gorringer KL. Targeted therapy for mucinous ovarian carcinoma: evidence from clinical trials. *Int J Gynecol Cancer* 2023;33:102-8.
75. O'Brien JS, McVey A, Kelly BD, Chee J, Lawrentschuk N. Recent developments in the diagnosis and management of N1 penile cancer. *Curr Opin Urol* 2023;33:64-9.
76. Odutola MK, van Leeuwen MT, Bassett JK, Bruinsma F, Turner J, Seymour JF, Prince HM, Milliken ST, Hertzberg M, Roncolato F, Opat SS, Lindeman R, Tiley C, Trotman J, Verner E, Harvey M, Underhill CR, Benke G, Giles GG, Vajdic CM. Dietary intake of animal-based products and likelihood of follicular lymphoma and survival: A population-based family case-control study. *Front Nutr* 2023;9:1048301.
77. Ong S, Chen K, Grummet J, Yaxley J, Scheltema MJ, Stricker P, Tay KJ, Lawrentschuk N. Guidelines of guidelines: focal therapy for prostate cancer, is it time for consensus? *BJU Int* 2023;131:20-31.
78. Ong WL, MacManus M, Milne RL, Foroudi F, Millar JL. Large variation in radiation therapy fractionation for multiple myeloma in Australia. *Asia Pac J Clin Oncol* 2023;19:149-57.
79. Parihar AS, Hofman MS, Iravani A. <sup>177</sup>Lu-Prostate-specific Membrane Antigen Radioligand Therapy in Patients with Metastatic Castration-resistant Prostate Cancer. *Radiology* 2023;306:e220859.
80. Pathmanandavel S, Crumbaker M, Ho B, Yam AO, Wilson P, Niman R, Ayers M, Sharma S, Hickey A, Eu P, Stockler M, Martin AJ, Joshua AM, Nguyen A, Emmett L. Evaluation of <sup>177</sup>Lu-PSMA-617 SPECT/CT Quantitation as a Response Biomarker Within a Prospective <sup>177</sup>Lu-PSMA-617 and NOX66 Combination Trial (LuPIN). *J Nucl Med* 2023;64:221-6.
81. Pathmanandavel S, Crumbaker M, Nguyen A, Yam AO, Wilson P, Niman R, Ayers M, Sharma S, Eu P, Martin AJ, Stockler MR, Joshua AM, Emmett L. The Prognostic Value of Posttreatment <sup>68</sup>Ga-PSMA-11 PET/CT and <sup>18</sup>F-FDG PET/CT in Metastatic Castration-Resistant Prostate Cancer Treated with <sup>177</sup>Lu-PSMA-617 and NOX66 in a Phase I/II Trial (LuPIN). *J Nucl Med* 2023;64:69-74.

82. Pattenden TA, Samaranayke D, Morton A, Ong WL, Murphy DG, Pritchard E, Evans S, Millar J, Chalasani V, Rashid P, Winter M, Vela I, Pryor D, Mark S, Lawrentschuk N, Thangasamy IA. Modern Active Surveillance in Prostate Cancer: A Narrative Review. *Clin Genitourin Cancer* 2023;21:115-23.
83. Pereira-Salgado A, Anton A, Franchini F, Mahar RK, Kwan EM, Wong S, Shapiro J, Weickhardt A, Azad AA, Spain L, Gunjur A, Torres J, Parente P, Parnis F, Goh J, Steer C, Brown S, Gibbs P, Tran B, IJerman M. Real-world clinical outcomes and cost estimates of metastatic castration-resistant prostate cancer treatment: does sequencing of taxanes and androgen receptor-targeted agents matter? *Expert Rev Pharmacoecon Outcomes Res* 2023;23:231-9.
84. Perram J, Purtill D, Bajel A, Butler J, O'Brien T, Teh B, Gilroy N, Ho PJ, Doocey R, Hills T, Perera T, Douglas G, Ramachandran S, Chee L, Trotman J, Weinkove R, Keogh S, Fraser C, Cochrane T, Watson AM, Diamond P, Latimer M, Irving I, Blyth E, Cheah C, Cole T, Milliken S, Yang H, Greenwood M, Bardy P, Kennedy G, Larsen S, Conyers R, Hamad N. Australia and New Zealand Transplant and Cellular Therapies (ANZTCT) position statement: COVID-19 management in patients with haemopoietic stem cell transplant and chimeric antigen receptor T cell. *Intern Med J* 2023;53:119-25.
85. Phung MT, Webb PM, DeFazio A, Fereday S, Lee AW, Bowtell DDL, Fasching PA, Goode EL, Goodman MT, Karlan BY, Lester J, Matsuo K, Modugno F, Brenton JD, Van Gorp T, Pharoah PDP, Schildkraut JM, McLean K, Meza R, Mukherjee B, Richardson J, Grout B, Chase A, McKinnon Deurloo C, Terry KL, Hanley GE, Pike MC, Berchuck A, Ramus SJ, Pearce CL. Lifestyle and personal factors associated with having macroscopic residual disease after ovarian cancer primary cytoreductive surgery. *Gynecol Oncol* 2023;168:68-75.
86. Pilmis B, Weiss E, Scemla A, Le Monnier A, Grossi PA, Slavin MA, Van Delden C, Lortholary O, Paugam-Burtz C, Zahar JR. Multidrug-resistant Enterobacterales infections in abdominal solid organ transplantation. *Clin Microbiol Infect* 2023;29:38-43.
87. Porwit A, Béné MC, Duetz C, Matarraz S, Oelschlaegel U, Westers TM, Wagner-Ballon O, Kordasti S, Valent P, Preijers F, Alhan C, Bellos F, Bettelheim P, Burbury K, Chapuis N, Cremers E, Della Porta MG, Dunlop A, Eidschink-Brodersen L, Font P, Fontenay M, Hobo W, Ireland R, Johansson U, Loken MR, Ogata K, Orfao A, Psarra K, Saft L, Subira D, Te Marvelde J, Wells DA, van der Velden VHJ, Kern W, van de Loosdrecht AA. Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issues: Recommendations from the European LeukemiaNet/International Myelodysplastic Syndrome Flow Cytometry Working Group. *Cytometry B Clin Cytom* 2023;104:27-50.
88. Posner A, Prall OW, Sivakumaran T, Etemadamoghadam D, Thio N, Pattison A, Balachander S, Fisher K, Webb S, Wood C, DeFazio A, Wilcken N, Gao B, Karapetis CS, Singh M, Collins IM, Richardson G, Steer C, Warren M, Karanth N, Wright G, Williams S, George J, Hicks RJ, Boussioutas A, Gill AJ, Solomon BJ, Xu H, Fellowes A, Fox SB, Schofield P, Bowtell D, Mileskin L, Tothill RW. A comparison of DNA sequencing and gene expression profiling to assist tissue of origin diagnosis in cancer of unknown primary. *J Pathol* 2023;259:81-92.
89. Posner A, Sivakumaran T, Pattison A, Etemadmoghadam D, Thio N, Wood C, Fisher K, Webb S, DeFazio A, Wilcken N, Gao B, Karapetis CS, Singh M, Collins IM, Richardson G, Steer C, Warren M, Karanth N, Fellowes A, Fox SB, Hicks RJ, Schofield P, Bowtell D, Prall OWJ, Tothill RW, Mileskin L. Immune and genomic biomarkers of immunotherapy response in cancer of unknown primary. *J Immunother Cancer* 2023;11:e005809.
90. Prabhu SA, Moussa O, Gonçalves C, LaPierre JH, Chou H, Huang F, Richard VR, Ferruzo PYM, Guettler EM, Soria-Bretones I, Kirby L, Gagnon N, Su J, Silvester J, Krisna SS, Rose AAN, Sheppard KE, Cescon DW, Mallette FA, Zahedi RP, Borchers CH, Del Rincon SV, Miller WH. Inhibition of the MNK1/2-eIF4E Axis Augments Palbociclib-Mediated Antitumor Activity in Melanoma and Breast Cancer. *Mol Cancer Ther* 2023;22:192-204.
91. Prince HM, Hutchings M, Domingo-Domenech E, Eichenauer DA, Advani R. Anti-CD30 antibody-drug conjugate therapy in lymphoma: current knowledge, remaining controversies, and future perspectives. *Ann Hematol* 2023;102:13-29.

92. Raad II, Hachem R, Masayuki N, Datoguia T, Dagher H, Jiang Y, Subbiah V, Siddiqui B, Bayle A, Somer R, Fernández Cruz A, Gorak E, Bhinder A, Nobuyoshi M, Hamerschlag N, Shelanski S, Dragovich T, Vong E, Fakhreddine S, Pierre AH, Chemaly RF, Mulanovich V, Adachi J, Borjan J, Khawaja F, Granwehr B, John T, Yepez E, Torres H, Ammakkanavar NR, Yibirin M, Reyes-Gibby C, Pande M, Ali N, Rojo R, Ali S, Deeba R, Chaftari P, Matsuo T, Ishikawa K, Hasegawa R, Aguado-Noya R, García A, Puchol CT, Lee DG, Slavin M, Teh B, Arias CA, Data-Driven Determinants for COVID-19 Oncology Discovery Effort (D3CODE) Team, Dimitrios PKP, Malek AE, Chaftari AM. International multicenter study comparing COVID-19 in patients with cancer to patients without cancer: impact of risk factors and treatment modalities on survivorship. *Elife* 2023;12:e81127.
93. Richardson K, Keam SP, Zhu JJ, Meyran D, D'Souza C, Macdonald S, Campbell K, Robbins M, Bezman NA, Todd K, Quach H, Ritchie DS, Harrison SJ, Prince HM, Trapani JA, Jenkins MR, Beavis PA, Darcy PK, Neeson PJ. The efficacy of combination treatment with elotuzumab and lenalidomide is dependent on crosstalk between natural killer cells, monocytes and myeloma cells. *Haematologica* 2023;108:83-97.
94. Roberts MJ, Maurer T, Perera M, Eiber M, Hope TA, Ost P, Siva S, Hofman MS, Murphy DG, Emmett L, Fendler WP. Using PSMA imaging for prognostication in localized and advanced prostate cancer. *Nat Rev Urol* 2023;20:23-47.
95. Rudin CM, Pandha HS, Zibelman M, Akerley WL, Harrington KJ, Day D, Hill AG, O'Day SJ, Clay TD, Wright GM, Jennens RR, Gerber DE, Rosenberg JE, Ralph C, Campbell DC, Curti BD, Merchan JR, Ren Y, Schmidt EV, Guttman L, Gupta S. Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Cocksackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors. *J Immunother Cancer* 2023;11:e005007.
96. Saleh R. Editorial: Recent advances and challenges in cancer immunotherapies for patients with autoimmune diseases. *Front Immunol* 2023;13:1127739.
97. Sandhu S, Atkinson V, Cao MG, Medina T, Rivas AS, Menzies AM, Caro I, Roberts L, Song Y, Yan Y, Guo Y, Xue C, Long GV. Phase 1b study of cobimetinib plus atezolizumab in patients with advanced BRAF<sup>V600</sup> wild-type melanoma progressing on prior anti-programmed death-1 therapy. *Eur J Cancer* 2023;178:180-90.
98. Seddon AR, Das AB, Hampton MB, Stevens AJ. Site-specific decreases in DNA methylation in replicating cells following exposure to oxidative stress. *Hum Mol Genet* 2023;32:632-48.
99. Sengupta C, Skouboe S, Ravkilde T, Poulsen PR, Nguyen DT, Greer PB, Moodie T, Hardcastle N, Hayden AJ, Turner S, Siva S, Tai KH, Martin J, Booth JT, O'Brien R, Keall PJ. The dosimetric error due to uncorrected tumor rotation during real-time adaptive prostate stereotactic body radiation therapy. *Med Phys* 2023;50:20-9.
100. Sessa C, Balmana J, Bober SL, Cardoso MJ, Colombo N, Curigliano G, Domchek SM, Evans DG, Fischerova D, Harbeck N, Kuhl C, Lemley B, Levy-Lahad E, Lambertini M, Ledermann JA, Loibl S, Phillips KA, Paluch-Shimon S, ESMO Guidelines Committee. Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline. *Ann Oncol* 2023;34:33-47.
101. Shallis RM, Daver NG, Altman JK, Hasserjian RP, Kantarjian HM, Platzbecker U, Santini V, Wei AH, Sallman DA, Zeidan AM. TP53-altered acute myeloid leukemia and myelodysplastic syndrome with excess blasts should be approached as a single entity. *Cancer* 2023;129:175-80.
102. Shembrey C, Foroutan M, Hollande F. A new natural killer cell-specific gene signature predicting recurrence in colorectal cancer patients. *Front Immunol* 2023;13:1011247.
103. Sherburn IA, Finlay K, Best S. How does the genomic naive public perceive whole genomic testing for health purposes? A scoping review. *Eur J Hum Genet* 2023;31:35-47.
104. Shortt J, Galettis P, Cheah CY, Davis J, Ludford-Menting M, Link EK, Martin JH, Koldej R, Ritchie D. A phase 1 clinical trial of the repurposable acetyllysine mimetic, n-methyl-2-pyrrolidone (NMP), in relapsed or refractory multiple myeloma. *Clin Epigenetics* 2023;15:15.



105. Sim B, Ng JY, Teh BW, Talaulikar D. Immunoglobulin replacement in hematological malignancies: a focus on evidence, alternatives, dosing strategy, and cessation rule. *Leuk Lymphoma* 2023;64:18-29.
106. Slaney CY, Luo P, Kong FM, Guo L, Zhang J. Editorial: Combining chemo/radio therapy and immunotherapy for cancers-perfect mix of old and new. *Front Immunol* 2023;13:1129623.
107. Smyth E, Cheah CY, Seymour JF. Management of indolent B-cell Lymphomas: A review of approved and emerging targeted therapies. *Cancer Treat Rev* 2023;113:102510.
108. Stacchiotti S, Dürr HR, Schaefer IM, Woertler K, Haas R, Trama A, Caraceni A, Bajpai J, Baldi GG, Bernthal N, Blay JY, Boye K, Broto JM, Chen WT, Dei Tos PA, Desai J, Emhofer S, Eriksson M, Gronchi A, Gelderblom H, Hardses J, Hartmann W, Healey J, Italiano A, Jones RL, Kawai A, Leithner A, Loong H, Mascard E, Morosi C, Otten N, Palmerini E, Patel SR, Reichardt P, Rubin B, Rutkowski P, Sangalli C, Schuster K, Seddon BM, Shkodra M, Staals EL, Tap W, van de Rijn M, van Langevelde K, Vanhoenacker FMM, Wagner A, Wiltink L, Stern S, Van de Sande VM, Bauer S. Best clinical management of tenosynovial giant cell tumour (TGCT): A consensus paper from the community of experts. *Cancer Treat Rev* 2023;112:102491.
109. Stewart T, Dowling M, Janson B, Siderov J, Xie J, Grigg A, Khot A. Acute kidney injury in patients receiving high-dose etoposide phosphate as conditioning prior to hematopoietic stem cell transplantation in hematologic malignancies may be associated with elevated body mass index. *Leuk Lymphoma* 2023;64:253-255.
110. Strach MC, Grimison PS, Hong A, Boyle R, Stalley P, Karim R, Connolly EA, Bae S, Desai J, Crowe P, Singhal N, Bhadri VA. Mesenchymal chondrosarcoma: An Australian multi-centre cohort study. *Cancer Med* 2023;12:368-78.
111. Szer J. The Journal in 2022. *Intern Med J* 2023;53:6-8.
112. Tan BY, Fox SB, Lakhani SR, Tan PH. Survey of recurrent diagnostic challenges in breast phyllodes tumours. *Histopathology* 2023;82:95-105.
113. Tan JLC, Wellard C, Moore EM, Mollee P, Rajagopal R, Quach H, Harrison SJ, McDonald EJ, Ho PJ, Prince HM, Augustson BM, Campbell P, McQuilten ZK, Wood EM, Spencer A. The second revision of the International Staging System (R2-ISS) stratifies progression-free and overall survival in multiple myeloma: Real world data results in an Australian and New Zealand Population. *Br J Haematol* 2023;200:e17-e21.
114. Tiong IS, Andrieska N, Dang P, Jones K, Thompson E, McBean M, Blombery P. Clinically relevant variation in FLT3-ITD quantitation as a result of PCR cycle number and ITD insertion size. *Pathology* 2023;55:71-6.
115. To YH, Gibbs P, Tie J, IJzerman M, Degeling K. Health economic evidence for adjuvant chemotherapy in stage II and III colon cancer: a systematic review. *Cost Eff Resour Alloc* 2023;21:11.
116. Udayasiri RI, Luo T, Gorringer KL, Fox SB. Identifying recurrences and metastasis after ductal carcinoma in situ (DCIS) of the breast. *Histopathology* 2023;82:106-18.
117. van de Loosdrecht AA, Kern W, Porwit A, Valent P, Kordasti S, Cremers E, Alhan C, Duetz C, Dunlop A, Hobo W, Preijers F, Wagner-Ballon O, Chapuis N, Fontenay M, Bettelheim P, Eidenschink-Brodersen L, Font P, Johansson U, Loken MR, Te Marvelde JG, Matarraz S, Ogata K, Oelschlaegel U, Orfao A, Psarra K, Subira D, Wells DA, Bene MC, Della Porta MG, Burbury K, Bellos F, van der Velden VHJ, Westers TM, Saft L, Ireland R. Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS-Flow Cytometry Working Group. *Cytometry B Clin Cytom* 2023;104:77-86.
118. van der Velden VHJ, Preijers F, Johansson U, Westers TM, Dunlop A, Porwit A, Bene MC, Valent P, Te Marvelde J, Wagner-Ballon O, Oelschlaegel U, Saft L, Kordasti S, Ireland R, Cremers E, Alhan C, Duetz C, Hobo W, Chapuis N, Fontenay M, Bettelheim P, Eidenschink-Brodersen L, Font P, Loken MR, Matarraz S, Ogata K, Orfao A, Psarra K, Subira D, Wells DA, Della Porta MG, Burbury K, Bellos F, Weiss E, Kern W,

van de Loosdrecht A. Flow cytometric analysis of myelodysplasia: Pre-analytical and technical issues- Recommendations from the European LeukemiaNet. *Cytometry B Clin Cytom* 2023;104:15-26.

119. Walpole I, Lee B, Shapiro J, Thomson B, Lipton L, Ananda S, Usatoff V, McLachlan SA, Knowles B, Fox A, Wong R, Cooray P, Burge M, Clarke K, Pattison S, Nikfarjam M, Tebbutt N, Harris M, Nagrial A, Zielinski R, Chee CE, Gibbs P. Use and outcomes from neoadjuvant chemotherapy in borderline resectable pancreatic ductal adenocarcinoma in an Australasian population. *Asia Pac J Clin Oncol* 2023;19:214-25.
120. Wang AJ, McCann B, Soon WCL, De Ieso PB, Bressel M, Hui A, Chua M, Kok DL. Merkel cell carcinoma: a forty-year experience at the Peter MacCallum Cancer Centre. *BMC Cancer* 2023;23:30.
121. Ward J, Prince HM, McCormack C, Lade S, Buelens O, van der Weyden C, Bhabha F, Campbell BA. Excellent treatment outcomes from low dose radiation therapy for primary cutaneous CD4+ small/medium T-Cell lymphoproliferative disorder. *Radiother Oncol* 2023;178:109430.
122. Weber JS, Schadendorf D, Del Vecchio M, Larkin J, Atkinson V, Schenker M, Pigozzo J, Gogas H, Dalle S, Meyer N, Ascierto PA, Sandhu S, Eigentler T, Gutzmer R, Hassel JC, Robert C, Carlino MS, Di Giacomo AM, Butler MO, Munoz-Couselo E, Brown MP, Rutkowski P, Haydon A, Grob JJ, Schachter J, Queirolo P, de la Cruz-Merino L, van der Westhuizen A, Menzies AM, Re S, Bas T, de Pril V, Braverman J, Tenney DJ, Tang H, Long GV. Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915). *J Clin Oncol* 2023;41:517-27.
123. Weinberg L, Yanase F, Tosif S, Riedel B, Bellomo R, Hahn RG. Trajectory of plasma syndecan-1 and heparan sulphate during major surgery: A retrospective observational study. *Acta Anaesthesiol Scand* 2023;67:4-11.
124. Weir A, Kang EY, Meagher NS, Nelson GS, Ghatage P, Lee CH, Riggan MJ, Gentry-Maharaj A, Ryan A, Singh N, Widschwendter M, Alsop J, Anglesio MS, Beckmann MW, Berger J, Bisinotto C, Boros J, Brand AH, Brenton JD, Brooks-Wilson A, Carney ME, Cunningham JM, Cushing-Haugen KL, Cybulski C, Elishaev E, Erber R, Fereday S, Fischer A, Paz-Ares L, Gayarre J, Gilks BC, Grube M, Harnett PR, Harris HR, Hartmann A, Hein A, Hendley J, Hernandez BY, Heublein S, Huang Y, Huzarski T, Jakubowska A, Jimenez-Linan M, Kennedy CJ, Kommoss FKF, Koziak JM, Kraemer B, Le ND, Lesnock J, Lester J, Lubiński J, Menkiszak J, Ney B, Olawaiye A, Orsulic S, Osorio A, Robles-Díaz L, Ruebner M, Shah M, Sharma R, Shvetsov YB, Steed H, Talhouk A, Taylor SE, Traficante N, Vierkant RA, Wang C, Wilkens LR, Winham SJ, Benitez J, Berchuck A, Bowtell DD, Candido Dos Reis FJ, Cook LS, DeFazio A, Doherty JA, Fasching PA, García MJ, Goode EL, Goodman MT, Gronwald J, Huntsman DG, Karlan BY, Kommoss S, Modugno F, Schildkraut JM, Sinn HP, Staebler A, Kelemen LE, Ford CE, Menon U, Pharoah PDP, Köbel M, Ramus SJ. Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study. *Br J Cancer* 2023;128:137-47.
125. Wheatley J, Liu Z, Loth J, Plummer MP, Penny-Dimri JC, Segal R, Smith J, Perry LA. The prognostic value of elevated neutrophil-lymphocyte ratio for cardiac surgery-associated acute kidney injury: A systematic review and meta-analysis. *Acta Anaesthesiol Scand* 2023;67:131-41.
126. Wong HL, Tie J. Low intensity treatment in metastatic colorectal cancer. *Lancet Gastroenterol Hepatol* 2023;8:97-9.
127. Wong JKM, Dolcetti R, Rhee H, Simpson F, Souza-Fonseca-Guimaraes F. Weaponizing natural killer cells for solid cancer immunotherapy. *Trends Cancer* 2023;9:111-21.
128. Yenerel MN, Sicre de Fontbrune F, Piatek C, Sahin F, Fureder W, Ortiz S, Ogawa M, Ozol-Godfrey A, Sierra JR, Szer J. Phase 3 Study of Subcutaneous Versus Intravenous Ravulizumab in Eculizumab-Experienced Adult Patients with PNH: Primary Analysis and 1-Year Follow-Up. *Adv Ther* 2023;40:211-32.
129. Young AL, Imran A, Spoelma MJ, Williams R, Tucker KM, Halliday J, Forrest LE, Wakefield CE, Butow PN. Proband-mediated interventions to increase disclosure of genetic risk in families with a BRCA or Lynch syndrome condition: a systematic review. *Eur J Hum Genet* 2023;31:18-34.

130. Yu SL, Hsiao YJ, Cooper WA, Choi YL, Avilés-Salas A, Chou TY, Coudry R, Raskin GA, Fox SB, Huang CC, Jeon YK, Ko YH, Ku WH, Kwon GY, Leslie C, Lin MC, Lou PJ, Scapulatempo-Neto C, Mendoza Ramírez S, Savelov N, Shim HS, Lara Torres CO, Cunha IW, Zavalishina L, Chen YM. The Ring Study: an international comparison of PD-L1 diagnostic assays and their interpretation in non-small cell lung cancer, head and neck squamous cell cancer and urothelial cancer. *Pathology* 2023;55:19-30.
131. Zeidan AM, Borate U, Pollyea DA, Brunner AM, Roncolato F, Garcia JS, Filshie R, Odenike O, Watson AM, Krishnadasan R, Bajel A, Naqvi K, Zha J, Cheng WH, Zhou Y, Hoffman D, Harb JG, Potluri J, Garcia-Manero G. A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes. *Am J Hematol* 2023;98:272-81.
132. Zerbato JM, Avihingsanon A, Singh KP, Zhao W, Deleage C, Rosen E, Cottrell ML, Rhodes A, Dantanarayana A, Tumpach C, Tennakoon S, Crane M, Price DJ, Braat S, Mason H, Roche M, Kashuba ADM, Revill PA, Audsley J, Lewin SR. HIV DNA persists in hepatocytes in people with HIV-hepatitis B co-infection on antiretroviral therapy. *EBioMedicine* 2023;87:104391.
133. Zwimpfer TA, Tal O, Geissler F, Coelho R, Rimmer N, Jacob F, Heinzelmann-Schwarz V. Low grade serous ovarian cancer - A rare disease with increasing therapeutic options. *Cancer Treat Rev* 2023;112:102497.